Although BTIG still believes Liquidia has favorable odds of prevailing against United’s ‘327 patent, the firm reduced the probability of success for Liquidia’s drug, Yutrepia, in treating pulmonary ...

Shares of United Therapeutics (UTHR) and Liquidia (LQDA) are moving sharply in opposite directions in Friday afternoon trading. Shares of United ...

Arquitos Capital Management gained 13.1% in Q2 2025. Learn how they turned market uncertainty into opportunity with Liquidia ...

In a report released yesterday, Andreas Argyrides from Oppenheimer maintained a Sell rating on Liquidia Technologies, with a price target of $6.00. The company’s shares closed yesterday at $19.26.

We sifted through the Finviz stock screener to compile a list of the top 10 biotech stocks with an upside potential of over ...

Because Liquidia made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now.

Liquidia shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.

Liquidia Corporation (NASDAQ:LQDA) is one of the best low priced pharma stocks to buy now. On June 24, Liquidia announced the receipt of an additional $50 million from Healthcare Royalty/HCRx. The ...

Liquidia Corporation (NASDAQ:LQDA) is one of the best low priced pharma stocks to buy now. On June 24, Liquidia announced the receipt of an additional $50 million from Healthcare Royalty/HCRx. The ...

Liquidia Corp (NASDAQ: LQDA), a $1.24 billion market cap biotech company, saw its Chief Human Resource Officer Sarah Krepp sell 2,673 shares of common stock on July 14, 2025, at a price of $14.28 ...

United Therapeutics achieves 12th consecutive quarter of growth, fueled by Tyvaso success. Discover insights on upcoming catalysts & $1B share buyback.